Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc.
Your view on OTLC
Overview
What the company does, where it operates, and who runs it.
About Oncotelic Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vuong Trieu
- Headquarters
- 29397 Agoura Road, Agoura Hills, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vuong Trieu
- Headquarters
- 29397 Agoura Road, Agoura Hills, CA, US
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.